LLY

826.35

+0.12%↑

UNH

549.29

-5.04%↓

JNJ

149.3

-0.15%↓

NVO

110.78

+1.8%↑

ABBV

176.22

+0.01%↑

LLY

826.35

+0.12%↑

UNH

549.29

-5.04%↓

JNJ

149.3

-0.15%↓

NVO

110.78

+1.8%↑

ABBV

176.22

+0.01%↑

LLY

826.35

+0.12%↑

UNH

549.29

-5.04%↓

JNJ

149.3

-0.15%↓

NVO

110.78

+1.8%↑

ABBV

176.22

+0.01%↑

LLY

826.35

+0.12%↑

UNH

549.29

-5.04%↓

JNJ

149.3

-0.15%↓

NVO

110.78

+1.8%↑

ABBV

176.22

+0.01%↑

LLY

826.35

+0.12%↑

UNH

549.29

-5.04%↓

JNJ

149.3

-0.15%↓

NVO

110.78

+1.8%↑

ABBV

176.22

+0.01%↑

Search

AstraZeneca PLC ADR

Closed

68.21 0.99

Overview

Share price change

24h

Current

Min

67.54

Max

68.55

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+29.82 upside

Technical Score

By Trading Central

Confidence

Bullish Evidence

AstraZeneca PLC ADR Chart

Past performance is not a reliable indicator of future results.

Related News

12 Nov 2024, 19:55 UTC

Earnings

AstraZeneca Expands U.S. Investment Plan -- 3rd Update

12 Nov 2024, 11:02 UTC

Earnings

AstraZeneca Raises Outlook, Plans U.S. Investment -- Update

12 Nov 2024, 07:37 UTC

Earnings

AstraZeneca Raises Outlook on Earnings, Sales Beat

10 Sept 2024, 09:29 UTC

Major Market Movers

AstraZeneca Shares Slump After Cancer Drug Misses Key Target

18 Nov 2024, 10:33 UTC

Market Talk

Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk

15 Nov 2024, 13:08 UTC

Top News

Trump's RFK Pick Weighs on Vaccine Makers -- WSJ

15 Nov 2024, 10:29 UTC

Hot Stocks

Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ

12 Nov 2024, 15:30 UTC

Top News

AstraZeneca Expands U.S. Investment Plan -- 2nd Update

12 Nov 2024, 13:39 UTC

Market Talk

AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk

12 Nov 2024, 10:49 UTC

Market Talk
Earnings

AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk

12 Nov 2024, 09:52 UTC

Market Talk

AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Raises 2024 View

12 Nov 2024, 07:01 UTC

Earnings

Analysts Saw AstraZeneca 3Q Sales at $13.1B

12 Nov 2024, 07:01 UTC

Earnings

Analysts Saw AstraZeneca 3Q Core EPS at $2.04

12 Nov 2024, 07:00 UTC

Earnings

AstraZeneca PLC 3Q EPS 91c

12 Nov 2024, 07:00 UTC

Earnings

AstraZeneca PLC 3Q Net Pft $1.43B

12 Nov 2024, 07:00 UTC

Earnings

AstraZeneca PLC 3Q Oper Pft $2.11B

7 Nov 2024, 08:03 UTC

Top News

China Has Detained a Senior AstraZeneca Executive -- Update

6 Nov 2024, 18:55 UTC

Top News

China Has Detained Senior AstraZeneca Executive -- WSJ

1 Nov 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

31 Oct 2024, 19:48 UTC

Top News

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update

31 Oct 2024, 14:43 UTC

Top News

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ

12 Sept 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 Sept 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

10 Sept 2024, 13:08 UTC

Market Talk

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

9 Sept 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

Peer Comparison

Price change

AstraZeneca PLC ADR Forecast

Price Target

By TipRanks

29.82% upside

12 Months Forecast

Average 87.67 USD  29.82%

High 88 USD

Low 87 USD

Based on 6 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

66.455 / 67.62Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

$